TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07058662: A Phase 1/2, Open-label Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.

Sponsor: Belief BioMed (Beijing) Co., Ltd · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,008,000

Rescue Site Savings

+$9,236,525

Unlock Full NCT07058662 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07058662 Rescue Dossier →